INOVIQ Ltd (IIQ.AX)
ASX · AUD · Healthcare · Diagnostics & Research
A$0.14 (+0.00%) as of
Key statistics
- Market cap
- 19.71M
- Forward P/E
- 14.00
- EPS (TTM)
- -0.0600
- Dividend yield
- 0.00%
- 52-week range
- 0.1300 – 0.5650
- Beta
- 1.48
- Revenue (TTM)
- 2.21M
- Profit margin
- 0.00%
- Analyst target
- A$0.70
- Volume
- 10.18k
About INOVIQ Ltd
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasive diagnostics using its proprietary exosome development technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Notting Hill, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.